Volasertib preclinical activity in high-risk hepatoblastoma

Relapsed and metastatic hepatoblastoma represents an unmet clinical need with limited chemotherapy treatment options. In a chemical screen, we identified volasertib as an agent with in vitro activity, inhibiting hepatoblastoma cell growth while sparing normal hepatocytes. Volasertib targets PLK1 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kats, Dina, Ricker, Cora A., Berlow, Noah E., Noblet, Bénédicte, Nicolle, Delphine, Mevel, Katell, Branchereau, Sophie, Judde, Jean-Gabriel, Stiverson, Cody D., Stiverson, Christina L., Svalina, Matthew N., Settelmeyer, Teagan, Matlock, Kevin, Lathara, Melvin, Mussini, Charlotte, Geller, James I., Noakes, Christopher, Sloma, Ido, Bharathy, Narendra, Cairo, Stefano, Keller, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849653/
https://www.ncbi.nlm.nih.gov/pubmed/31741706
http://dx.doi.org/10.18632/oncotarget.27237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849653/
https://www.ncbi.nlm.nih.gov/pubmed/31741706
http://dx.doi.org/10.18632/oncotarget.27237

Ejemplares similares